AstraZeneca Faces Securities Investigation After Trial Failure

Law firm Levi & Korsinsky has initiated an investigation into AstraZeneca PLC (NYSE: AZN) concerning potential securities law violations. The investigation stems from the failure of the company's Phase III CARDIO-TTransform trial for its drug Wainua to meet its primary efficacy endpoint.

AstraZeneca announced on July 9, 2026, that the trial, focused on transthyretin-mediated amyloid cardiomyopathy, did not demonstrate a statistically significant benefit in reducing a composite of cardiovascular mortality and recurrent cardiovascular events. The company had previously positioned Wainua as a key growth driver and part of its ambition to reach $80 billion in revenue by 2030.

As a result of the trial's failure, AstraZeneca's share price dropped by over 8.3% in early trading on July 9, 2026. Levi & Korsinsky is encouraging investors who incurred losses after purchasing AZN shares to contact them to explore potential recovery of those losses.

Levi & Korsinsky LLP is a nationally recognized law firm specializing in shareholder rights litigation. The firm stated that the investigation is examining potentially false or misleading statements made by the company regarding its securities.